Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet
2009; 373: 31–41.
Leucht, S, Komossa, K, Rummel-Kluge, C, Corves, C, Hunger, H, Schmid, F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry
2009; 166: 152–63.
McEvoy, JP, Lieberman, JA, Stroup, TS, Davis, SM, Meltzer, H Y, Rosenheck, RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry
2006; 163: 600–10.
Lewis, SW, Barnes, TRE, Davies, L, Murray, RM, Dunn, G, Hayhurst, KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull
2006; 32: 715–23.
Tiihonen, J, Wahlbeck, K, Lonnqvist, J, Klaukaa, T, Ioannidis, JPA, Volavka, J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of 2230 patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow up study. BMJ
2006; 333: 224.
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry
2006; 63: 622–9.
Brunette, MF, Drake, RE, Xie, H, McHugo, GJ, Green, AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull
2006; 32: 637.
Tiihonen, J, Lönnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet
2009; 374: 620–7.
Kelly, DL, McMahon, RP, Liu, F, Love, RC, Wehring, HJ, Shim, JC, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry
2010; 71: 304–11.
Merrill, DB, Dec, GW, Goff, DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol
2005; 25: 32–41.
Weissman, EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration – New York metropolitan region. Schizophr Bull
2002; 28: 31–42.
Tognoni, G. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders. Eur J Clin Pharmacol
1999; 55: 685–90.
Downs, J, Zinkler, M. Clozapine: national review of postcode prescribing. Psychiatr Bull
2007; 31: 384–7.
National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment of Schizophrenia in Adults in Primary and Secondary Care (Updated Edition) (NICE Clinical Guideline CG82). National Institute for Health and Clinical Excellence, 2009.
Wheeler, AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother
2008; 42: 852–60.
Taylor, DM, Young, C, Paton, C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry
2003; 64: 30–4.
Agid, O, Remington, G, Kapur, S, Arenovich, T, Zipursky, R. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharm
2007; 27: 369–73.
Taylor, D, Shapland, L, Laverick, G, Bond, J, Munro, J. Clozapine – a survey of patient perceptions. Psychiatr Bull
2000; 24: 450–2.
Nielsen, J, Dahm, M, Lublin, H, Taylor, D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacology
2010; 24: 965–71.